Amicogen, Inc.
Financials
Valuation Metrics
Amicogen, Inc.'s Market Cap is ₩632B. At end of 2025 it was ₩1259B. Ranked #1624 of 2,421 in KR market (top 67%), #964 of 1,640 on KOSDAQ (top 59%), #178 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 63.17B KRW | KR#1,624/2,421 Sec#178/231 |
| Revenue | 46.69B KRW | KR#1,836/2,421 Sec#128/231 |
| Net Income | -20.02B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 197.17B KRW | KR#1,319/2,421 Sec#95/231 |
| Net Assets | 118.87B KRW | KR#1,298/2,421 Sec#101/231 |
| Employees | 223 | KR#1,014/2,421 Sec#84/231 |
| Value | ||
| P/B | 0.53x | KR#860/2,421 Sec#42/231 |
| P/S | 1.35x | KR#1,583/2,421 Sec#92/231 |
| FCF Yield | -44.54% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -16.84% | KR#2,058/2,421 Sec#160/231 |
| ROA | -10.16% | KR#2,106/2,421 Sec#160/231 |
| Op. Margin | -27.93% | KR#2,168/2,421 Sec#152/231 |
| Revenue Growth | -60.34% | KR#2,306/2,421 Sec#206/231 |
| Financial Health | ||
| Debt Ratio | 65.87% | KR#1,165/2,421 Sec#139/231 |
| Total Debt | 57.92B KRW | KR#947/2,421 Sec#64/231 |
| FCF | -28.13B KRW | KR#1,975/2,421 Sec#190/231 |
| Cash | 8.24B KRW | KR#1,799/2,421 Sec#158/231 |
| Current Ratio | 1.04x | KR#1,672/2,421 Sec#167/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -77.14% | KR#2,344/2,421 Sec#224/231 |
| 1M Return | -8.02% | KR#2,003/2,421 Sec#166/231 |
| From 52W High | -79.68% | KR#2,338/2,421 Sec#215/231 |
| 1Y MDD | -80.55% | KR#2,304/2,421 Sec#210/231 |
| Trading | ||
| Volume | 239,515 shares | KR#423/2,421 Sec#26/231 |
| Trading Value | 215.3M KRW | KR#1,247/2,421 Sec#127/231 |
| Foreign Own. | 2.62% | KR#1,417/2,421 Sec#132/231 |
| Per Share | ||
| EPS | -283 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,682 KRW | KR#2,144/2,421 Sec#180/231 |
Company Info
Amicogen, established in 2000, is an industrial bio-specialized company that develops and produces special enzymes for pharmaceuticals, biomaterials for pharmaceuticals, and enzyme-based new biomaterials using genetic evolution technology. The company supplies CX enzyme for 7-ACA production to the global market, pursues localization of purification resins and media for antibody biopharmaceuticals, and expands its health functional food business. By securing production technology and promoting its next-generation antibiotic enzyme CDMO business, Amicogen aims to expand its global market through large-scale commercialization of biopharmaceutical materials. Amicogen is headquartered in Jinju-si, Gyeongsangnam-do.